MP welcomes major new trial which shows treating prostate cancer with radiotherapy improves survival

26 Oct 2018
Tim at the manifesto launch

South Lakes MP Tim Farron has welcomed a major new trial which found that radiotherapy can provide extended survival time for thousands of men with prostate cancer.

The trial which was conducted by the University of Birmingham and funded by Cancer Research UK found that the use of radiotherapy treatment increased the chance of survival by 11% among men with prostate cancer.

Prostate cancer is the most common cancer affecting UK men, with 47,000 diagnosed every year, of whom around 11,500 sadly pass away.

Tim, who is the chair of the All Party Parliamentary Group on radiotherapy, says the new research should lead to further investment in the treatment.

Currently, the NHS spends only 5% of its cancer budget on radiotherapy services although around 50% of cancer patients will need radiotherapy as a part of their treatment.

Tim said: "Prostate cancer affects 1 in 8 men.

"But they continue to be let down by chronic underinvestment.

"We demand better - with the evidence now clear about the benefits of the treatment, the Government must respond to this news and commit to invest in life-saving radiotherapy."

To sign the petition calling for the Government to invest in radiotherapy service, go here.

This website uses cookies

Like most websites, this site uses cookies. Some are required to make it work, while others are used for statistical or marketing purposes. If you choose not to allow cookies some features may not be available, such as content from other websites. Please read our Cookie Policy for more information.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.